146 related articles for article (PubMed ID: 33428419)
1. Discovery and Biological Evaluation of
Park E; Lee SJ; Moon H; Park J; Jeon H; Hwang JS; Hwang H; Hong KB; Han SH; Choi S; Kang S
J Med Chem; 2021 Jan; 64(2):958-979. PubMed ID: 33428419
[TBL] [Abstract][Full Text] [Related]
2. Identification and Biological Evaluation of a Potent and Selective JAK1 Inhibitor for the Treatment of Pulmonary Fibrosis.
Park E; Park S; Lee SJ; Jeong D; Jin H; Moon H; Cha B; Kim D; Ma S; Seo W; Han SH; Lee YS; Kang S
J Med Chem; 2023 Dec; 66(23):16342-16363. PubMed ID: 38031930
[TBL] [Abstract][Full Text] [Related]
3. 4-Amino-pyrrolopyridine-5-carboxamide: a novel scaffold for JAK1-selective inhibitors.
Shin H; Kim MK; Chong Y
Chem Pharm Bull (Tokyo); 2014; 62(3):217-20. PubMed ID: 24583775
[TBL] [Abstract][Full Text] [Related]
4. Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors.
Lu K; Wu W; Zhang C; Liu Z; Xiao B; Yuan Z; Li A; Chen D; Zhai X; Jiang Y
Bioorg Med Chem Lett; 2020 Jul; 30(14):127225. PubMed ID: 32527540
[TBL] [Abstract][Full Text] [Related]
5. Discovery of pyrrolo[1,2-b]pyridazine-3-carboxamides as Janus kinase (JAK) inhibitors.
Duan JJ; Lu Z; Jiang B; Yang BV; Doweyko LM; Nirschl DS; Haque LE; Lin S; Brown G; Hynes J; Tokarski JS; Sack JS; Khan J; Lippy JS; Zhang RF; Pitt S; Shen G; Pitts WJ; Carter PH; Barrish JC; Nadler SG; Salter-Cid LM; McKinnon M; Fura A; Schieven GL; Wrobleski ST
Bioorg Med Chem Lett; 2014 Dec; 24(24):5721-5726. PubMed ID: 25453808
[TBL] [Abstract][Full Text] [Related]
6. Development of selective inhibitors for the treatment of rheumatoid arthritis: (R)-3-(3-(Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)pyrrolidin-1-yl)-3-oxopropanenitrile as a JAK1-selective inhibitor.
Chough C; Joung M; Lee S; Lee J; Kim JH; Kim BM
Bioorg Med Chem; 2018 May; 26(8):1495-1510. PubMed ID: 29452839
[TBL] [Abstract][Full Text] [Related]
7. The discovery of 2,5-isomers of triazole-pyrrolopyrimidine as selective Janus kinase 2 (JAK2) inhibitors versus JAK1 and JAK3.
Lee SM; Yoon KB; Lee HJ; Kim J; Chung YK; Cho WJ; Mukai C; Choi S; Kang KW; Han SY; Ko H; Kim YC
Bioorg Med Chem; 2016 Nov; 24(21):5036-5046. PubMed ID: 27555284
[TBL] [Abstract][Full Text] [Related]
8. Benzimidazole Derivatives as Potent JAK1-Selective Inhibitors.
Kim MK; Shin H; Park KS; Kim H; Park J; Kim K; Nam J; Choo H; Chong Y
J Med Chem; 2015 Sep; 58(18):7596-602. PubMed ID: 26351728
[TBL] [Abstract][Full Text] [Related]
9. Identification of N-{cis-3-[Methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases.
Vazquez ML; Kaila N; Strohbach JW; Trzupek JD; Brown MF; Flanagan ME; Mitton-Fry MJ; Johnson TA; TenBrink RE; Arnold EP; Basak A; Heasley SE; Kwon S; Langille J; Parikh MD; Griffin SH; Casavant JM; Duclos BA; Fenwick AE; Harris TM; Han S; Caspers N; Dowty ME; Yang X; Banker ME; Hegen M; Symanowicz PT; Li L; Wang L; Lin TH; Jussif J; Clark JD; Telliez JB; Robinson RP; Unwalla R
J Med Chem; 2018 Feb; 61(3):1130-1152. PubMed ID: 29298069
[TBL] [Abstract][Full Text] [Related]
10. Discovery of (2
Su Q; Banks E; Bebernitz G; Bell K; Borenstein CF; Chen H; Chuaqui CE; Deng N; Ferguson AD; Kawatkar S; Grimster NP; Ruston L; Lyne PD; Read JA; Peng X; Pei X; Fawell S; Tang Z; Throner S; Vasbinder MM; Wang H; Winter-Holt J; Woessner R; Wu A; Yang W; Zinda M; Kettle JG
J Med Chem; 2020 May; 63(9):4517-4527. PubMed ID: 32297743
[TBL] [Abstract][Full Text] [Related]
11. Transforming Growth Factor-β (TGF-β) Directly Activates the JAK1-STAT3 Axis to Induce Hepatic Fibrosis in Coordination with the SMAD Pathway.
Tang LY; Heller M; Meng Z; Yu LR; Tang Y; Zhou M; Zhang YE
J Biol Chem; 2017 Mar; 292(10):4302-4312. PubMed ID: 28154170
[TBL] [Abstract][Full Text] [Related]
12. Novel JAK1-selective benzimidazole inhibitors with enhanced membrane permeability.
Kim H; Kim MK; Choo H; Chong Y
Bioorg Med Chem Lett; 2016 Jul; 26(14):3213-3215. PubMed ID: 27261178
[TBL] [Abstract][Full Text] [Related]
13. Selective JAK1 inhibitor and selective Tyk2 inhibitor patents.
Norman P
Expert Opin Ther Pat; 2012 Oct; 22(10):1233-49. PubMed ID: 22971156
[TBL] [Abstract][Full Text] [Related]
14. Identification of azabenzimidazoles as potent JAK1 selective inhibitors.
Vasbinder MM; Alimzhanov M; Augustin M; Bebernitz G; Bell K; Chuaqui C; Deegan T; Ferguson AD; Goodwin K; Huszar D; Kawatkar A; Kawatkar S; Read J; Shi J; Steinbacher S; Steuber H; Su Q; Toader D; Wang H; Woessner R; Wu A; Ye M; Zinda M
Bioorg Med Chem Lett; 2016 Jan; 26(1):60-7. PubMed ID: 26614408
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design and development of (benz)imidazole pyridones as JAK1-selective kinase inhibitors.
Simov V; Deshmukh SV; Dinsmore CJ; Elwood F; Fernandez RB; Garcia Y; Gibeau C; Gunaydin H; Jung J; Katz JD; Kraybill B; Lapointe B; Patel SB; Siu T; Su H; Young JR
Bioorg Med Chem Lett; 2016 Apr; 26(7):1803-8. PubMed ID: 26927423
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition.
Telliez JB; Dowty ME; Wang L; Jussif J; Lin T; Li L; Moy E; Balbo P; Li W; Zhao Y; Crouse K; Dickinson C; Symanowicz P; Hegen M; Banker ME; Vincent F; Unwalla R; Liang S; Gilbert AM; Brown MF; Hayward M; Montgomery J; Yang X; Bauman J; Trujillo JI; Casimiro-Garcia A; Vajdos FF; Leung L; Geoghegan KF; Quazi A; Xuan D; Jones L; Hett E; Wright K; Clark JD; Thorarensen A
ACS Chem Biol; 2016 Dec; 11(12):3442-3451. PubMed ID: 27791347
[TBL] [Abstract][Full Text] [Related]
17. Discovery of 3,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-2(1H)-one derivatives as novel JAK inhibitors.
Yamagishi H; Shirakami S; Nakajima Y; Tanaka A; Takahashi F; Hamaguchi H; Hatanaka K; Moritomo A; Inami M; Higashi Y; Inoue T
Bioorg Med Chem; 2015 Aug; 23(15):4846-4859. PubMed ID: 26059596
[TBL] [Abstract][Full Text] [Related]
18. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.
Hamaguchi H; Amano Y; Moritomo A; Shirakami S; Nakajima Y; Nakai K; Nomura N; Ito M; Higashi Y; Inoue T
Bioorg Med Chem; 2018 Oct; 26(18):4971-4983. PubMed ID: 30145050
[TBL] [Abstract][Full Text] [Related]
19. Structure activity optimization of 6H-pyrrolo[2,3-e][1,2,4]triazolo[4,3-a]pyrazines as Jak1 kinase inhibitors.
Friedman M; Frank KE; Aguirre A; Argiriadi MA; Davis H; Edmunds JJ; George DM; George JS; Goedken E; Fiamengo B; Hyland D; Li B; Murtaza A; Morytko M; Somal G; Stewart K; Tarcsa E; Van Epps S; Voss J; Wang L; Woller K; Wishart N
Bioorg Med Chem Lett; 2015 Oct; 25(20):4399-404. PubMed ID: 26372653
[TBL] [Abstract][Full Text] [Related]
20. Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease.
Yang T; Cui X; Tang M; Qi W; Zhu Z; Shi M; Yang L; Pei H; Zhang W; Xie L; Xu Y; Yang Z; Chen L
J Med Chem; 2022 Feb; 65(4):3151-3172. PubMed ID: 35113547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
